Major Histocompatibility Complex-presented Melanoma-associated antigen A1, A3, and New York esophageal squamous cell carcinoma 1 peptides (MHC-presented MAGE-A1/A3/NY-ESO-1)

MHC-presented MAGE-A1, MAGE-A3, and NY-ESO-1 peptides are intracellularly derived fragments of Cancer-Testis Antigens (CTAs) displayed on the cell surface by Major Histocompatibility Complex (MHC) molecules, most commonly HLA-A*02:01 (PMID: 24030377). These antigens are characterized by their restricted expression in normal adult tissues, such as the testis and placenta, and their high expression in various malignancies, including melanoma, synovial sarcoma, and non-small cell lung cancer (PMID: 9067576). Because these peptides are presented on the cell surface, they allow the immune system to recognize intracellular proteins that are otherwise inaccessible to traditional antibody-based therapies. Therapeutic strategies targeting these complexes include T-cell receptor (TCR) engineered T-cell therapies, cancer vaccines, and TCR-mimetic antibodies designed to induce a potent cytotoxic T-lymphocyte response (PMID: 15150594). A primary challenge in targeting these peptides is the requirement for specific HLA alleles and the risk of off-target cross-reactivity with similar peptides in vital organs. For example, clinical trials targeting MAGE-A3 were previously complicated by fatal cross-reactivity with the cardiac protein Titin, highlighting the necessity for rigorous specificity screening (PMID: 23908301).

Other names

MAGE-A1/A3/NY-ESO-1 pMHCCancer-Testis Antigen peptidesHLA-presented CTA peptidesMAGE-A1 peptide-MHCMAGE-A3 peptide-MHCNY-ESO-1 peptide-MHCCTAG1B peptide-MHC

Recognition of specific peptide-MHC complexes by engineered or endogenous T-cell receptors (TCRs), triggering cytotoxic T-lymphocyte (CTL) activation, secretion of pro-inflammatory cytokines, and direct lysis of antigen-expressing tumor cells.